申请人:Ajinomoto Co., Inc.
公开号:EP2725016A1
公开(公告)日:2014-04-30
The present invention provides a blood glucose elevation inhibitor having a serine protease inhibitory action, which is a novel therapeutic or prophylactic agent for obesity. A compound represented by the following formula (I)
wherein each symbol is as described in the specification, or a pharmaceutically acceptable salt thereof.
本发明提供了一种具有丝氨酸蛋白酶抑制作用的血糖升高抑制剂,它是一种新型的肥胖症治疗或预防剂。由下式(I)代表的化合物
其中各符号如说明书所述,或其药学上可接受的盐。